TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9014542

Group type: COMPARATOR
Intervention: Doxapram (0.18 mg.kg‐1)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Pethidine (0.35 mg.kg‐1)
Number of subjects: 220
Study: 8198023

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg every PM for 6 weeks followed by 20 mg twice daily for an additional 6 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 3480840

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal suppository (2.5 mg PGE2 in Witepsol S55)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous infusion of oxytocin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal suppository
Number of subjects: 100
Study: 30485892

Group type: EXPERIMENTAL
Intervention: Artificial extracorporeal liver support (ECLS) systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-volume plasma exchange
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioartificial (cell-based) ECLS systems
Number of subjects: 0
Study: 27194403

Group type: EXPERIMENTAL
Intervention: Intravenous Plasma-Lyte 148 at 2 mL·kg(‐1) (low volume)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intravenous Plasma-Lyte 148 at 20 mL·kg(‐1) (high volume)
Number of subjects: 150
Study: 24899558

Group type: EXPERIMENTAL
Intervention: Clinical scenario‐based simulation education for communication
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard class‐based education for communication
Number of subjects: 78
Study: 22108194

Group type: EXPERIMENTAL
Intervention: FIT after FIT
Number of subjects: 3616

Group type: COMPARATOR
Intervention: First-round FIT
Number of subjects: 3616
Study: 20065276

Group type: EXPERIMENTAL
Intervention: Suicide inquiries by primary care physicians
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Types of suicide inquiries
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Language used in suicide inquiries
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Physician responses to denial of ideation
Number of subjects: 152
Study: 17521473

Group type: EXPERIMENTAL
Intervention: Potassium titanyl phosphate laser tonsillectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bipolar radiofrequency tonsillectomy
Number of subjects: 80
Study: 16896786

Group type: EXPERIMENTAL
Intervention: Sustained-release chrono VPA (ChVbid, ChVom, ChVoe)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional VPA (CVbid)
Number of subjects: 48
Study: 12831522

Group type: EXPERIMENTAL
Intervention: Tinidazole (50 mg/kg, as a single dose)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Chloroquine (10 mg/kg twice daily for 5 days)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Albendazole (400 mg/day for 5 days)
Number of subjects: 165
Study: 15520757

Group type: EXPERIMENTAL
Intervention: Mixed breastfeeding (BF)
Number of subjects: 17046

Group type: EXPERIMENTAL
Intervention: Formula/other milk
Number of subjects: 17046

Group type: EXPERIMENTAL
Intervention: Mixed BF
Number of subjects: 17046

Group type: COMPARATOR
Intervention: Cereal intake
Number of subjects: 17046

Group type: EXPERIMENTAL
Intervention: Mixed BF and formula/other milk
Number of subjects: 17046
Study: 10724638

Group type: EXPERIMENTAL
Intervention: Monodisperse aerosol (160 micrograms of fenoterol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MDI aerosol plus spacer (800 micrograms of fenoterol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7485346

Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 209

Group type: COMPARATOR
Intervention: Late amniotomy
Number of subjects: 209

Group type: COMPARATOR
Intervention: 60-minute oxytocin increments
Number of subjects: 209
Study: 2127744

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g administered orally 1 hour before exercise)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (administered orally 1 hour before exercise)
Number of subjects: 10
Study: 36754

Group type: EXPERIMENTAL
Intervention: Phenothiazines (Promethazine, Promazine, Propiomazine, Chlorpromazine, Methotrimeprazine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrimeprazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenothiazines (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenothiazines for narcotic analgesic‐induced emesis
Number of subjects: 0
Study: 31740425

Group type: EXPERIMENTAL
Intervention: Real-time Effort Driven ventilator management (REDvent)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study: 28577665

Group type: EXPERIMENTAL
Intervention: Salt substitute provided free of charge to participants in intervention villages
Number of subjects: 20996

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20996
Study: 26372751

Group type: EXPERIMENTAL
Intervention: Occlusive antimicrobial barrier dressing
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard surgical dressing
Number of subjects: 262
Study: 23450444

Group type: EXPERIMENTAL
Intervention: Hyperthyroid Graves' disease women
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 60
Study: 21215445

Group type: EXPERIMENTAL
Intervention: 2.5 mg vitamin D(3) administered at baseline and 14, 28, and 42 days after starting standard tuberculosis treatment.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo administered at baseline and 14, 28, and 42 days after starting standard tuberculosis treatment.
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 2.5 mg vitamin D(3) in patients with tt genotype of TaqI vitamin D receptor polymorphism.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo in patients with tt genotype of TaqI vitamin D receptor polymorphism.
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 2.5 mg vitamin D(3) at 56 days.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo at 56 days.
Number of subjects: 146
Study: 18798851

Group type: EXPERIMENTAL
Intervention: Basiliximab plus steroids, mycophenolate mofetil and early initiation of cyclosporin A (CsA) at 3 mg/kg/d within 24 h post-RT
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Basiliximab plus steroids, mycophenolate mofetil and early initiation of cyclosporin A (CsA) at 5 mg/kg/d within 24 h post-RT
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Basiliximab plus steroids, mycophenolate mofetil and delayed initiation of cyclosporin A (CsA) at 5 mg/kg/d after 7-10 d
Number of subjects: 114
Study: 17146635

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) using polymyxin E, tobramycin, and amphotericin B in throat and gut throughout ICU treatment combined with cefotaxime for 4 days
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control group (no SDD treatment)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 401
Study: 14975783

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET) using a head-mounted display (HMD) (low presence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET) using a computer automatic virtual environment (CAVE) (high presence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early drop-outs
Number of subjects: 0
Study: 11303585

Group type: EXPERIMENTAL
Intervention: Soymilk (400 ml daily for 8 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (usual diet)
Number of subjects: 35
Study: 9207869

Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemoradiotherapy with an anthracenedione (50 Gy in 25 fractions over 5 weeks, boost of 15 Gy to the tumor bed when indicated) and chemotherapy (5-fluorouracil, mitoxantrone, and cyclophosphamide at 21-day intervals for 4 to 6 cycles)
Number of subjects: 154
Study: 8205090

Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline (PTX) 400 mg every 4 hours from day -10 until day +35 or discharge
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no PTX)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (PTX and control)
Number of subjects: 49
Study: 3109069

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 25 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 125 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 250 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: In vitro trials with ASA
Number of subjects: 35
Study: 31883869

Group type: EXPERIMENTAL
Intervention: Protocols published until 2010
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Protocols published from 2011 onward
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Overall protocols
Number of subjects: 620
Study: 30793518

Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg dexamphetamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28958084

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (N = 90)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Sleep control (N = 91)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Self-reported sleep quality (Study 1)
Number of subjects: 181
Study: 25194147

Group type: EXPERIMENTAL
Intervention: Child executive function problems
Number of subjects: 1005
Study: 23545372

Group type: EXPERIMENTAL
Intervention: Guided self-help treatment of pediatric obesity (GSH-PO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 50
Study: 21576556

Group type: EXPERIMENTAL
Intervention: Intranasal aqueous triamcinolone acetonide, administered once daily for 6 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo, administered once daily for 6 weeks
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intranasal aqueous triamcinolone acetonide
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 19234297

Group type: EXPERIMENTAL
Intervention: Belief in progress (manipulated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mortality salience (manipulated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Essay on the illusory notion of human progress
Number of subjects: 0
Study: 17538164

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cetuximab
Number of subjects: 424

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 424
Study: 15095852

Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg/day for 8 weeks, 6 mg/day for 4 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Prednisolone (1 mg/kg/day for 4 weeks, tapering for 8 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 48
Study: 12364443

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 19
Study: 9839077

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strenuous exercise
Number of subjects: 0
Study: 7806686

Group type: EXPERIMENTAL
Intervention: Regular alprazolam (CT), given four times per day
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Extended release alprazolam (XR), given once in the morning
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Regular alprazolam (CT)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Extended release alprazolam (XR)
Number of subjects: 209
Study: 2791810

Group type: EXPERIMENTAL
Intervention: Waterbed (WB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular bed (RB)
Number of subjects: 20
Study: 122450

Group type: EXPERIMENTAL
Intervention: E program (inpatient care, day hospital, community housing, sheltered work)
Number of subjects: 94

Group type: COMPARATOR
Intervention: C program (rapid discharge)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: E program
Number of subjects: 94
Study: 31054263

Group type: EXPERIMENTAL
Intervention: Hyperoxia (fraction of inspired O2 = 0.5)
Number of subjects: 8
Study: 28213634

Group type: EXPERIMENTAL
Intervention: Descriptive‐plus‐injunctive norm feedback
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Descriptive norm feedback
Number of subjects: 111

Group type: COMPARATOR
Intervention: No social feedback (control condition)
Number of subjects: 111
Study: 25651297

Group type: EXPERIMENTAL
Intervention: Cosmetics education programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study: 23916925

Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg twice daily (n = 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 61
Study: 21514613

Group type: EXPERIMENTAL
Intervention: ICG fluorescent cholangiography using the Photodynamic Eye (PDE) (n = 52)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Leak test with ICG dye alone (Control group) (n = 50)
Number of subjects: 102
Study: 18069016

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Subacromial steroid injections
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both physiotherapy and steroid injections
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 16794461

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (150 mg of cocoa flavanols for 5 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (450 mg of flavanols - single acute dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 16
Study: 14509311

Group type: EXPERIMENTAL
Intervention: Normal volunteers
Number of subjects: 44

Group type: COMPARATOR
Intervention: Diabetics
Number of subjects: 44
Study: 11007579

Group type: EXPERIMENTAL
Intervention: Ischemic handgrip exercise at 60% maximum voluntary contraction (MVC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ischemic handgrip exercise at 15% and 30% maximum voluntary contraction (MVC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ischemic handgrip exercise at 15%, 30%, 45%, and 60% maximum voluntary contraction (MVC)
Number of subjects: 10
Study: 9377070

Group type: EXPERIMENTAL
Intervention: Peripheral blood progenitor cell (PBPC) apheresis
Number of subjects: 24
Study: 8404803

Group type: EXPERIMENTAL
Intervention: Higher intensity exercise training
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Higher intensity home exercise training
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Lower intensity home exercise training
Number of subjects: 357

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: All exercise programs (regardless of assignment)
Number of subjects: 357
Study: 3530645

Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Intravenous nitroprusside
Number of subjects: 2
Study: 30590423

Group type: EXPERIMENTAL
Intervention: Increased insulin resistance (measured by HOMA-IR)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Emotional eating or disinhibition (measured by TFEQ factor 2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Higher habitual physical activity
Number of subjects: 39
Study: 29981361

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Eating at an unintended time
Number of subjects: 189
Study: 26849119

Group type: EXPERIMENTAL
Intervention: Carbocysteine 1500 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: CPAP treatment
Number of subjects: 40
Study: 25132282

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (30 mg of lansoprazole, 1g of amoxicillin, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily for 10 days)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Standard triple therapy (30 mg of lansoprazole, 1g of amoxicillin, and 500 mg of clarithromycin, twice daily for 10 days)
Number of subjects: 348
Study: 22861163

Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 0
Study: 20157647

Group type: EXPERIMENTAL
Intervention: Thermocycling (5000 times, 5 to 55 °C)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Immersion in deionized water (37°C, 2 months)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Immersion in citric acid (pH: 3.0; 1 week)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (stored dry for 24 h at 37°C)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Using substrate and adherend interchangeably (QA-TE, TE-QA)
Number of subjects: 192
Study: 17505458

Group type: EXPERIMENTAL
Intervention: Human herpesvirus infections during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human parvovirus B19 infection during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal infection with hepatitis B and C
Number of subjects: 0
Study: 15482247

Group type: EXPERIMENTAL
Intervention: six-week, home-based mobility program
Number of subjects: 26

Group type: COMPARATOR
Intervention: six-week, home-based program of upper-limb exercises (sham mobility exercises)
Number of subjects: 26
Study: 11563797

Group type: EXPERIMENTAL
Intervention: Children of alcoholics (COAs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Children of nonalcoholics (CONAs)
Number of subjects: 100
Study: 10933337

Group type: EXPERIMENTAL
Intervention: Butorphanol (3 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Butorphanol (6 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Morphine (15 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Morphine (30 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg/70 kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study: 8156482

Group type: EXPERIMENTAL
Intervention: 5-FU (425 mg/m2) and LV (20 mg/m2) for 5 days
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 5-FU (425 mg/m2) and LV (20 mg/m2) plus CDDP (20 mg/m2 for 4 consecutive days)
Number of subjects: 138

Group type: COMPARATOR
Intervention: 5-FU and LV
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 5-FU, LV, and CDDP
Number of subjects: 138
Study: 3073655

Group type: EXPERIMENTAL
Intervention: IV infusion of CF with constant dose of FUra 400 mg/m2
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oral CF with escalating doses of FUra
Number of subjects: 63
Study: 29602626

Group type: EXPERIMENTAL
Intervention: Intra-alveolar administration of epsilon-aminocaproic acid (EACA) and daily gentle rinsing with EACA mouthwash
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine postoperative recommendations
Number of subjects: 52
Study: 28133766

Group type: EXPERIMENTAL
Intervention: RBP-7000 (90 mg and 120 mg)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 26455013

Group type: EXPERIMENTAL
Intervention: Normal LV function (Group A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Diastolic heart dysfunction (Group B)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Anaerobic threshold
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients with LV diastolic dysfunction
Number of subjects: 57
Study: 23615539

Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF) in patients with isolated aphasia (n=109 from EAFT)
Number of subjects: 4151

Group type: COMPARATOR
Intervention: Atrial Fibrillation (AF) in patients without isolated aphasia (n=3,941)
Number of subjects: 4151

Group type: EXPERIMENTAL
Intervention: Isolated aphasia in patients with TIA
Number of subjects: 4151
Study: 21609797

Group type: EXPERIMENTAL
Intervention: Bovine carotid artery (BCA) graft
Number of subjects: 53

Group type: COMPARATOR
Intervention: Expanded polytetrafluoroethylene (ePTFE) graft
Number of subjects: 53
Study: 19061736

Group type: EXPERIMENTAL
Intervention: 16-week aquatic training program (strength training, aerobic training, relaxation exercises)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 16-week aquatic training program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy women, n=25)
Number of subjects: 60
Study: 16572113

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14604145

Group type: EXPERIMENTAL
Intervention: Carbamide peroxide at 10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamide peroxide at 20%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 7.5%
Number of subjects: 0
Study: 11115050

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b (3 million units thrice weekly) plus ribavirin (1,000-1,200 mg per day) for 24 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b (3 million units thrice weekly) plus ribavirin (1,000-1,200 mg per day) for 48 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin for 48 weeks in relapsers
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin for 24 weeks in relapsers
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin for 48 weeks in non-responders
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin for 24 weeks in non-responders
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Normal ALT level and undetectable HCV RNA at week 12
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HCV RNA positive at week 12
Number of subjects: 120
Study: 9058441

Group type: EXPERIMENTAL
Intervention: Diet providing 20 g/d lactose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lactose-free diet
Number of subjects: 14
Study: 8375836

Group type: EXPERIMENTAL
Intervention: Day treatment program (18 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (delayed-treatment)
Number of subjects: 0